Brightstone Pharma files application to sell generic iopamidol contrast

Article

Pharmaceutical developers are swarming over the market for generic iopamidol like ants at a summer picnic. The latest company to announce its intentions to sell the low-osmolar x-ray contrast medium in the U.S. is Brightstone Pharma of Cary, NC, the U.S.

Pharmaceutical developers are swarming over the market for generic iopamidol like ants at a summer picnic. The latest company to announce its intentions to sell the low-osmolar x-ray contrast medium in the U.S. is Brightstone Pharma of Cary, NC, the U.S. subsidiary of SkyePharma in the U.K.

Brightstone announced last month that it has filed an abbreviated new drug application (ANDA) with the Food and Drug Administration for iopamidol injection, a generic alternative to Bracco's Isovue. Isovue went off-patent last year, opening the door to generic competition, and a raft of companies have publicly said that they intend to sell generic iopamidol (SCAN 3/5/97).

To develop its version of iopamidol, Brightstone has partnered with another company that has an exclusive agreement with a supplier of the raw material for the agent, according to a Brightstone spokesperson. Brightstone's iopamidol will be produced in the Netherlands by a contract manufacturer that the company declined to identify. Brightstone expects that its ANDA will be approved in the first quarter of 1999.

Brightstone will sell iopamidol in 41%, 61%, and 76% concentrations, and will market the product through its own hospital-based sales force. The company's target market will include hospitals, clinics, integrated healthcare networks, HMOs, and other types of healthcare facilities that routinely use x-ray contrast.

Brightstone was formed in January 1996 as a subsidiary of SkyePharma of London, which itself was founded in late 1995. The company's focus is on generic drugs, although it is developing some branded pharmaceuticals as well. Brightstone is selling four generic drugs, including cimetidine, a version of gastrointestinal drug Tagamet, and glyburide, a version of diabetes drug Micronase. Brightstone does not develop drugs in-house, preferring to access them either through SkyePharma sister companies or through agreements similar to the iopamidol deal.

When Brightstone's generic iopamidol does hit the market, it will join products under development by Abbott Laboratories of Abbott Park, IL, Hovione of Portugal, Faulding Pharmaceutical of Elizabeth, NJ, and ESI-Lederle, a division of American Home Products. Even x-ray contrast developers are getting into the market, with Norway's Nycomed acquiring rights to generic iopamidol from Fujisawa USA (SCAN 6/11/97).

Newsletter

Stay at the forefront of radiology with the Diagnostic Imaging newsletter, delivering the latest news, clinical insights, and imaging advancements for today’s radiologists.

Recent Videos
SNMMI: Emerging PET Insights on Neuroinflammation with Progressive Apraxia of Speech (PAOS) and Parkinson-Plus Syndrome
Improving Access to Nuclear Imaging: An Interview with SNMMI President Jean-Luc C. Urbain, MD, PhD
SNMMI: 18F-Piflufolastat PSMA PET/CT Offers High PPV for Local PCa Recurrence Regardless of PSA Level
SNMMI: NIH Researcher Discusses Potential of 18F-Fluciclovine for Multiple Myeloma Detection
SNMMI: What Tau PET Findings May Reveal About Modifiable Factors for Alzheimer’s Disease
Emerging Insights on the Use of FES PET for Women with Lobular Breast Cancer
Can Generative AI Reinvent Radiology Reporting?: An Interview with Samir Abboud, MD
Mammography Study Reveals Over Sixfold Higher Risk of Advanced Cancer Presentation with Symptom-Detected Cancers
Combining Advances in Computed Tomography Angiography with AI to Enhance Preventive Care
Study: MRI-Based AI Enhances Detection of Seminal Vesicle Invasion in Prostate Cancer
Related Content
© 2025 MJH Life Sciences

All rights reserved.